Alp Bio's platform combines tonsil organoid technology and state-of-the-art protein AI to assess and reduce immunogenic risk in therapeutic antibodies before they can impact patient outcomes.
This profile is maintained by the Sesamers data desk. Claim it to edit details, post jobs and answer interviews.
€1,900,000
Total raised
-
Valuation
5
Employees
2025
Founded
Latest round
Pre-seed - April 30, 2026
Pre-seed - €1,900,000
April 30, 2026
✓ verified by our desk
Open roles
ALP Bio is not hiring through Sesamers right now.
Work here? Claim the profile and post roles.
Claim your profile